Literature DB >> 33230

Lack of complaints in schizophrenics with tardive dyskinesia.

G S Alexopoulos.   

Abstract

Eighteen of a population of 518 outpatients were found to fulfill diagnostic criteria for tardive dyskinesia. None of these patients complained to their therapists of their symptoms, and eight of them were not even aware of them. Five of the unaware patients were actively delusional or hallucinating. Since all eighteen were chronic schizophrenics on neuroleptics, these findings suggest that this group may not report their symptoms. The findings are important because early diagnosis of tardive dyskinesia allows more chance for intervention with satisfactory results.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 33230     DOI: 10.1097/00005053-197902000-00008

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  5 in total

1.  Defending the unabomber: anosognosia in schizophrenia.

Authors:  X F Amador; R Paul-Odouard
Journal:  Psychiatr Q       Date:  2000

2.  The effects of electromyographic feedback training on suppression of the oral-lingual movements associated with tardive dyskinesia.

Authors:  R C Fudge; S A Thailer; M Alpert; J Intrator; C E Sison
Journal:  Biofeedback Self Regul       Date:  1991-06

3.  Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective.

Authors:  S P Segal; D Cohen; S R Marder
Journal:  Am J Public Health       Date:  1992-06       Impact factor: 9.308

4.  Prevalence of spontaneous dyskinesia in first episode, drug naive schizophrenia, and its relation to the positive and negative symptoms of schizophrenia.

Authors:  Samrat Singh Bhandari; Dipesh Bhagabati
Journal:  Open J Psychiatry Allied Sci       Date:  2016-12-30

Review 5.  Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Marco Solmi; Giorgio Pigato; John M Kane; Christoph U Correll
Journal:  Drug Des Devel Ther       Date:  2018-05-14       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.